Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis

BACKGROUND: Immune checkpoint inhibitors (ICIs), antibodies targeting PD-1/PD-L1 or CTLA4 have revolutionized cancer management but are associated with devastating immune-related adverse events (irAEs) including myocarditis. The main risk factor for ICI myocarditis is the use of combination PD-1 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Pan, Liu, Jing, Qin, Juan, Lai, Lulu, Heo, Gyu Seong, Luehmann, Hannah, Sultan, Deborah, Bredemeyer, Andrea, Bajapa, Geetika, Feng, Guoshuai, Jimenez, Jesus, Parks, Antanisha, Amrute, Junedh, Villanueva, Ana, Liu, Yongjian, Lin, Chieh-Yu, Mack, Matthias, Amancherla, Kaushik, Moslehi, Javid, Lavine, Kory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168426/
https://www.ncbi.nlm.nih.gov/pubmed/37162929
http://dx.doi.org/10.1101/2023.04.28.538426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168426/
https://www.ncbi.nlm.nih.gov/pubmed/37162929
http://dx.doi.org/10.1101/2023.04.28.538426

Ejemplares similares